Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — Trials · CancerIndex

Clinical trials

Registered studies

136 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 17
Recruiting: 8
Ph III recruiting: 0
Growth YoY: —
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (30)

clinicaltrialsPublishedShowing 1–10 of 10 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05627245	Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment	active not recruiting	Phase 1	48	National Cancer Institute (NCI)NIH	1	Sep 18, 2026	clinicaltrials
NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	Phase 2	41	City of Hope Medical CenterOTHER	1